J. Robert Beck, MD, senior vice president, deputy director, chief academic officer, chief administrative officer, and H.O. West and J.R. Wike Chair in Cancer Research at Fox Chase, received the 2014 Cancer Control Award. The award celebrates the spirit of volunteerism and work that advances cancer research, patient care, and advocacy. Beck oversees all activities that support Fox Chase’s academic and research operations. He also maintains research interests in technology assessment, cost-effectiveness of cancer therapies, cancer health disparities, and the organization of biomedical informatics services and general academic resources.
The Pennsylvania Division, Southeast Region of the American Cancer Society (ACS) honored Fox Chase Cancer Center and Temple University School of Medicine for the work of key individuals whose gifts of time and talent increase the chances of living in a cancer-free world.
Fox Chase Cancer Center was honored with the Partners in Health Initiatives Award for its high level of commitment to the mission of ACS. The award is given to organizations that have demonstrated outstanding efforts to link ACS goals and priorities with the goals and priorities of the system that they represent.
The American Academy of Hospice and Palliative Medicine has honored Michael H. Levy, MD, PhD, director of Fox Chase’s pain and palliative care program, with its 2015 Lifetime Achievement Award. The award recognizes Levy’s outstanding contributions and significant publications that have helped shape the field of hospice and palliative medicine. Levy, who is considered a leader of the American hospice and palliative care movement, is also chair of the NCCN Palliative Care Guidelines panel and a member of the Technical Advisory Panel for the first update of The Joint Commission’s palliative care standards.
The TopLine Fusion-guided biopsy combines MR images with real-time ultrasound images to create a better target for the biopsy The technology can help lower the risk of missing aggressive tumors and can avoid future unnecessary biopsies An innovative technology called MR/ultrasound fusion prostate biopsy is allowing Fox Chase physicians to take a much more targeted approach to the collection of tissue samples from patients undergoing prostate biopsies. Currently, patients with low-risk prostate cancer often choose a strategy of active surveillance, the recommended course to avoid overtreatment. Yet there is a risk of disease progression, especially if the cancer is more … Continue Reading »
The Topline Pancreatic cancer cells use the vitamin D receptor (VDR) to repair the damage caused by gemcitabine Treatments that inhibit VDR may render tumors more sensitive to cancer-killing drugs VDR appears to act epigenetically on RAD51 to fix DNA damage caused by chemotherapy and allow tumor cells to survive and continue dividing Pancreatic cancer is one of the deadliest forms of the disease. Doctors’ typical line of attack involves DNA-damaging agents such as gemcitabine, but despite the potent activities of these drugs, patient survival is only extended by a few months, if that. Indeed, pancreatic cancer has the lowest … Continue Reading »
Since joining Fox Chase in 1991 as chief of head and neck surgery, John A. Ridge has been dedicated to developing treatments and surgical techniques that cure head and neck cancers while allowing patients to maintain a high quality of life. Nationally recognized, Ridge focuses his clinical practice on head and neck and endocrine tumors, including nonsurgical management, organ preservation, new surgical techniques, and early and advanced thyroid tumors. As a co-chair of the National Cancer Institute’s Head and Neck Cancer Steering Committee, he helps coordinate and direct federally funded clinical research in the field, setting the agenda for the … Continue Reading »
One of the most exciting new areas in cancer research is a class of monoclonal antibodies that targets immune system checkpoints—specifically, the programmed cell death protein 1 (PD-1) expressed on T-cell membranes. By binding its ligand PD-L1, PD-1 downregulates T cells and prevents autoimmune reactions. Continue Reading »
Survivorship Care Guidelines for Non-Small Cell Lung and Colorectal Cancers Medical oncologist Crystal Denlinger, MD, presented new results from her project titled “Adherence to NCCN Survivorship Care Guidelines in Non-Small Cell Lung Cancer (NSCLC) and Colorectal Cancer (CRC)” at the National Comprehensive Cancer Network’s 20th annual conference in March. Denlinger and colleagues found that comprehensive assessment guidelines for NSCLC and CRC survivors were not regularly met, although adherence increased somewhat after providers received an educational intervention focused on survivorship care. The research, presented at the conference’s general poster session, was funded through Denlinger’s NCCN Foundation 2012 Young Investigator Award. Denlinger … Continue Reading »